When we get the go ahead from the EMA for a phase 3 for B-OM, I believe we will see the announcement of our first partnership. I think that will happen soon.
B OM NOT included in a deal? Maybe any deal would be to develop B IBD only.
The B OM data are not convincing.
How do I know that for sure? because convincing data would have led to a deal for B OM soon after trial conclusion
Desperate need for mucositis drug and easy administration and it's prevention not treatment and isn't all that wonderful?
Of course it is wonderful- and that is why we know pharma does not trust the data enough to even sign on. Great market opportunity, P3?? Anybody? Anybody???!? maybe you'd like to see more subsets? With really small numbers of patients??
News 
Market Data 
Discover 
